Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Pre-screening Survey for Metabolic, Cardiovascular, Obesity, Mental Health, and Endocrine Trial Eligibility (DOVE-MET-COME-100)
Clindove Research LLC
7,000 participants
Jul 30, 2025
OBSERVATIONAL
Conditions
Summary
DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.
Eligibility
Inclusion Criteria2
- Any participant of age 18 years and over
- Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures.
Exclusion Criteria6
- Pregnant or breastfeeding individuals
- Individuals having severe cognitive impairment or inability to provide informed consent
- Individuals having acute psychiatric emergencies requiring immediate intervention/hospitalization
- Individuals who are currently participating in another research study that conflicts with pre-screening data collection
- Individuals having known history of drug/alcohol misuse
- Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.
Interventions
Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07106879